REG - Convatec Group PLC - Total Voting Rights

ConvaTecAnnouncement

Mon 17:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250901:nRSA5340Xa&default-theme=true

RNS Number : 5340X  Convatec Group PLC  01 September 2025

1 September 2025

Convatec Group Plc

("Convatec" or "the Company")

Total Voting Rights

In accordance with the UK Financial Conduct Authority's ("FCA") Disclosure and
Transparency Rule 5.6.1R, the Company notifies the market that as at 29 August
2025:

1.     The Company's issued share capital comprised 2,049,789,559 ordinary
shares of 10p each, each with one vote.

2.   1,242,173 ordinary shares are held in treasury. These shares are not
taken into consideration in relation to the payment of dividends and voting at
shareholder meetings.

Accordingly, the total number of voting rights in the Company is
2,048,547,386. This figure may be used by shareholders as the denominator for
the calculations by which to determine if they are required to notify their
interest in, or a change to, their interest in the Company under the FCA's
Disclosure and Transparency Rules.

There are 4,897,055 ordinary shares of the Company which have been purchased
pursuant to the share buyback programme announced on 20 August 2025 which are
in the course of the settlement process. Once settled, these shares will be
held in treasury.

 

Contacts

 

The person responsible for making this announcement is James Kerton, Company
Secretary, Convatec Group plc: cosec@convatec.com

 

Media: MediaRelations@convatec.com

 

Investor Relations: IR@convatec.com

 

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

 

Classification: 2.5 Total number of voting rights and capital

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in Advanced
Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than
10,000 colleagues, we provide our products and services in around 90
countries, united by a promise to be forever caring. Our solutions provide a
range of benefits, from infection prevention and protection of at-risk skin,
to improved patient outcomes and reduced care costs. Convatec's revenues in
2024 were over $2 billion. The company is a constituent of the FTSE 100 Index
(LSE:CTEC). To learn more please visit http://www.convatecgroup.com
(http://www.convatecgroup.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRMZGGLVMDGKZM